Abstract
Transgender people may wish to transition to the other sex, usually to the fullest extent possible. Part of that transition is enabled by the administration of cross-sex hormones and part by surgical adaptation. The treatment of male-to-female transgender people consists of blocking androgen action and allowing estrogens to feminize the body. For virilization of female-to-male transgender people, androgens usually suffice. In adulthood, certain features of the sex hormone-induced body shape cannot be undone (such as the larger size of bones in males, the hip configuration in females). After about 2–3 years, the maximally attainable effects of cross-sex hormones have been reached. With competent endocrinological advice, cross-sex hormone treatment is usually uneventful. The estrogen ethinyl estradiol is to be avoided in view of the risks of venous thrombosis and cardiovascular disease. Androgen administration does not lead to an increase in cardiovascular disease. Hormone-dependent cancers have been observed in transgender people but not to an alarming degree. The relative rarity of transsexualism and the scattering of endocrine treatment over many centers is an impediment to build a solid body of knowledge with regard to efficacy and safety of cross-sex hormone treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Asscheman, H., Giltay, E. J., Megens, J. A., de Ronde, W. P., van Trotsenburg, M. A., & Gooren, L. J. (2011). A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology, 164(4), 635–642.
Asscheman, H., Gooren, L. J., & Eklund, P. L. (1989). Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism, 38(9), 869–873.
Baglietto, L., Severi, G., English, D. R., Krishnan, K., Hopper, J. L., McLean, C., et al. (2010). Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiological Biomarkers Prevention, 19(2), 492–502.
Ballantyne, K. N., Kayser, M., & Grootegoed, J. A. (2011). Sex and gender issues in competitive sports: Investigation of a historical case leads to a new viewpoint. British Journal of Sports Medicine, 46(8), 614–617.
Becerra Fernandez, A., De Luis Roman, D., & Piedrola Maroto, G. (1999). Morbilidad en pacientes transexuales con autotratamiento hormonal para cambiar de sexo. Medicine Clinic (Barcelona), 113, 481–483.
Benjamin, H. (1966). The transsexual phenomenon. New York, NY: Julian Press.
Bentvelsen, F. M., Brinkmann, A. O., van der Schoot, P., van der Linden, J. E., van der Kwast, T. H., Boersma, W. J., et al. (1995). Developmental pattern and regulation by androgens of androgen receptor expression in the urogenital tract of the rat. Molecular and Cellular Endocrinology, 113(2), 245–253.
Bentz, E. K., Pils, D., Bilban, M., Kaufmann, U., Hefler, L. A., Reinthaller, A., et al. (2010). Gene expression signatures of breast tissue before and after cross-sex hormone therapy in female-to-male transsexuals. Fertility and Sterility, 94(7), 2688–2696.
Bunck, M. C., Debono, M., Giltay, E. J., Verheijen, A. T., Diamant, M., & Gooren, L. J. (2009). Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. BMJ Case Reports. pii: bcr02.2009.1589.
Burcombe, R. J., Makris, A., Pittam, M., & Finer, N. (2003). Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. Breast, 12(4), 290–293.
Cebula, H., Pham, T. Q., Boyer, P., & Froelich, S. (2010). Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient. Acta Neurochirurgica, 152(11), 1955–1956.
Choong, K., Lakshman, K. M., & Bhasin, S. (2008). The physiological and pharmacological basis for the ergogenic effects of androgens in elite sports. Asian Journal of Andrology, 10(3), 351–363.
De Sutter, P. (2001). Gender reassignment and assisted reproduction: Present and future reproductive options for transsexual people. Human Reproduction, 16(4), 612–614.
Deipolyi, A. R., Han, S. J., & Parsa, A. T. (2010). Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy. Journal of Clinical Neuroscience, 17(10), 1324–1326.
Dhand, A., & Dhaliwal, G. (2010). Examining patient conceptions: A case of metastatic breast cancer in an African American male to female transgender patient. Journal of General Internal Medicine, 25(2), 158–161.
Dhejne, C., Lichtenstein, P., Boman, M., Johansson, A. L., Langstrom, N., & Landen, M. (2011). Long-term follow-up of transsexual persons undergoing sex reassignment surgery: Cohort study in Sweden. PLoS One, 6(2), e16885.
Dimitrakakis, C., & Bondy, C. (2009). Androgens and the breast. Breast Cancer Research, 11(5), 212.
Dizon, D. S., Tejada-Berges, T., Koelliker, S., Steinhoff, M., & Granai, C. O. (2006). Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecologic and Obstetric Investigation, 62(4), 226–228.
Dorff, T. B., Shazer, R. L., Nepomuceno, E. M., & Tucker, S. J. (2007). Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clinical Genitourinary Cancer, 5(5), 344–346.
Dougherty, S. M., Mazhawidza, W., Bohn, A. R., Robinson, K. A., Mattingly, K. A., Blankenship, K. A., et al. (2006). Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocrine-Related Cancer, 13(1), 113–134.
Driak, D., & Samudovsky, M. (2004). Cervical cancer in a female-to-male trans-sexual. European Journal of Cancer, 40(11), 1795.
Galazis, N., Olaleye, O., Haoula, Z., Layfield, R., & Atiomo, W. (2012). Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: A systematic review and biomarker database integration. Fertility and Sterility, 98(6), 1590–1601.
Ganly, I., & Taylor, E. W. (1995). Breast cancer in a trans-sexual man receiving hormone replacement therapy. The British Journal of Surgery, 82(3), 341.
Garcia-Malpartida, K., Martin-Gorgojo, A., Rocha, M., Gomez-Balaguer, M., & Hernandez-Mijares, A. (2010). Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual. Fertility and Sterility, 94(3), 1097. e1013–e1095.
Gazzeri, R., Galarza, M., & Gazzeri, G. (2007). Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. The New England Journal of Medicine, 357(23), 2411–2412.
Gooren, L. J. (2011). Clinical practice. Care of transsexual persons. The New England Journal of Medicine, 364(13), 1251–1257.
Gooren, L. J., Assies, J., Asscheman, H., de Slegte, R., & van Kessel, H. (1988). Estrogen-induced prolactinoma in a man. The Journal of Clinical Endocrinology and Metabolism, 66(2), 444–446.
Gooren, L. J., & Behre, H. M. (2008). Testosterone treatment of hypogonadal men participating in competitive sports. Andrologia, 40(3), 195–199.
Gooren, L. J., & Bunck, M. C. (2004). Transsexuals and competitive sports. European Journal of Endocrinology, 151(4), 425–429.
Gooren, L. J., & Giltay, E. J. (2008). Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females. The Journal of Sexual Medicine, 5(4), 765–776.
Gooren, L. J., Giltay, E. J., & Bunck, M. C. (2008). Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience. The Journal of Clinical Endocrinology and Metabolism, 93(1), 19–25.
Gooren, L. J., Sungkaew, T., & Giltay, E. J. (2012). Exploration of functional health, mental well-being and cross-sex hormone use in a sample of Thai male-to-female transgendered persons (kathoeys). Asian Journal of Andrology. doi:10.1038/aja.2012.139.
Grabellus, F., Worm, K., Willruth, A., Schmitz, K. J., Otterbach, F., Baba, H. A., et al. (2005). ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual. Breast, 14(1), 71–74.
Grady, D., & Barrett-Connor, E. (2007). Postmenopausal hormone therapy. BMJ, 334(7599), 860–861.
Grynberg, M., Fanchin, R., Dubost, G., Colau, J. C., Bremont-Weil, C., Frydman, R., et al. (2010). Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reproductive Biomedicine Online, 20(4), 553–558.
Hage, J. J., Dekker, J. J., Karim, R. B., Verheijen, R. H., & Bloemena, E. (2000). Ovarian cancer in female-to-male transsexuals: Report of two cases. Gynecologic Oncology, 76(3), 413–415.
Hamburger, C. (1969). Endocrine treatment of male and female transsexualism (pp. 291–307). Baltimore, MD: Johns Hopkins Press.
Handelsman, D. J., & Gooren, L. J. (2008). Hormones and sport: Physiology, pharmacology and forensic science. Asian Journal of Andrology, 10(3), 348–350.
Handelsman, D. J., & Heather, A. (2008). Androgen abuse in sports. Asian Journal of Andrology, 10(3), 403–415.
Haring, R., Volzke, H., Felix, S. B., Schipf, S., Dorr, M., Rosskopf, D., et al. (2009). Prediction of metabolic syndrome by low serum testosterone levels in men: Results from the study of health in Pomerania. Diabetes, 58(9), 2027–2031.
Hembree, W. C., Cohen-Kettenis, P., Delemarre-van de Waal, H. A., Gooren, L. J., Meyer, W. J., III, Spack, N. P., et al. (2009). Endocrine treatment of transsexual persons: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 94(9), 3132–3154.
Institute of Medicine (Ed.). (2011). The health of lesbian, gay, bisexual, and transgender people: Building a foundation for better understanding. Washington, DC: The National Academies Press.
Ito, K. (2007). Hormone replacement therapy and cancers: The biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. The Tohoku Journal of Experimental Medicine, 212(1), 1–12.
Khosla, S. (2010). Update on estrogens and the skeleton. The Journal of Clinical Endocrinology and Metabolism, 95(8), 3569–3577.
Kovacs, K., Stefaneanu, L., Ezzat, S., & Smyth, H. S. (1994). Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Archives of Pathology and Laboratory Medicine, 118(5), 562–565.
Marjoribanks, J., Farquhar, C., Roberts, H., & Lethaby, A. (2012). Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews (Online), 7, CD004143.
Mauras, N., Hayes, V., Welch, S., Rini, A., Helgeson, K., Dokler, M., et al. (1998). Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity. The Journal of Clinical Endocrinology and Metabolism, 83(6), 1886–1892.
Meyer, W. J., Walker, P. A., & Suplee, Z. R. (1981). A survey of transsexual hormonal treatment in twenty gender-treatment centers. Journal of Sex Research, 17(4), 344–349.
Migeon, C. J., Rivarola, M. A., & Forest, M. G. (1968). Studies of androgens in transsexual subjects. Effects of estrogen therapy. The Johns Hopkins Medical Journal, 123(3), 128–133.
Miksad, R. A., Bubley, G., Church, P., Sanda, M., Rofsky, N., Kaplan, I., et al. (2006). Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA: The Journal of the American Medical Association, 296(19), 2316–2317.
Molokwu, C. N., Appelbaum, J. S., & Miksad, R. A. (2008). Detection of prostate cancer following gender reassignment. BJU International, 101(2), 259. author reply 259–260.
Money, J. (1971). Transexualism and the philosophy of healing. The Journal of the American Society of Psychosomatic Dentistry and Medicine, 18, 25–26.
Mueller, A., Dittrich, R., Binder, H., Kuehnel, W., Maltaris, T., Hoffmann, I., et al. (2005). High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. European Journal of Endocrinology, 153(1), 107–113.
Mueller, A., & Gooren, L. (2008). Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology, 159(3), 197–202.
Ott, J., Kaufmann, U., Bentz, E. K., Huber, J. C., & Tempfer, C. B. (2010). Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertility and Sterility, 93(4), 1267–1272.
Pache, T. D., & Fauser, B. C. (1993). Polycystic ovaries in female-to-male transsexuals. Clinical Endocrinology, 39(6), 702–703.
Pritchard, T. J., Pankowsky, D. A., Crowe, J. P., & Abdul-Karim, F. W. (1988). Breast cancer in a male-to-female transsexual. A case report. JAMA: The Journal of the American Medical Association, 259(15), 2278–2280.
Ruetsche, A. G., Kneubuehl, R., Birkhaeuser, M. H., & Lippuner, K. (2005). Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: A cross-sectional study. Osteoporosis International, 16(7), 791–798.
Schenck, T. L., Holzbach, T., Zantl, N., Schuhmacher, C., Vogel, M., Seidl, S., et al. (2010). Vaginal carcinoma in a female-to-male transsexual. The Journal of Sexual Medicine, 7(8), 2899–2902.
Schoemaker, M. J., Swerdlow, A. J., Higgins, C. D., Wright, A. F., & Jacobs, P. A. (2008). Cancer incidence in women with Turner syndrome in Great Britain: A national cohort study. The Lancet Oncology, 9(3), 239–246.
Serri, O., Noiseux, D., Robert, F., & Hardy, J. (1996). Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. The Journal of Clinical Endocrinology and Metabolism, 81(9), 3177–3179.
Shao, T., Grossbard, M. L., & Klein, P. (2011). Breast cancer in female-to-male transsexuals: Two cases with a review of physiology and management. Clinical Breast Cancer, 11(6), 417–419.
Slagter, M. H., Gooren, L. J., Scorilas, A., Petraki, C. D., & Diamandis, E. P. (2006). Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. The Journal of Histochemistry and Cytochemistry, 54(8), 905–910.
Slattery, M. L., Sweeney, C., Murtaugh, M., Ma, K. N., Caan, B. J., Potter, J. D., et al. (2006). Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. International Journal of Cancer, 118(12), 3140–3146.
Storer, T. W., Magliano, L., Woodhouse, L., Lee, M. L., Dzekov, C., Dzekov, J., et al. (2003). Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. The Journal of Clinical Endocrinology and Metabolism, 88(4), 1478–1485.
Symmers, W. S. (1968). Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. British Medical Journal, 2(5597), 83–85.
Thurston, A. V. (1994). Carcinoma of the prostate in a transsexual. British Journal of Urology, 73(2), 217.
Toorians, A. W., Thomassen, M. C., Zweegman, S., Magdeleyns, E. J., Tans, G., Gooren, L. J., et al. (2003). Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. The Journal of Clinical Endocrinology and Metabolism, 88(12), 5723–5729.
T’Sjoen, G., Weyers, S., Taes, Y., Lapauw, B., Toye, K., Goemaere, S., et al. (2009). Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons. Journal of Clinical Densitometry, 12(3), 306–313.
Turner, A., Chen, T. C., Barber, T. W., Malabanan, A. O., Holick, M. F., & Tangpricha, V. (2004). Testosterone increases bone mineral density in female-to-male transsexuals: A case series of 15 subjects. Clinical Endocrinology, 61(5), 560–566.
Utian, W. H. (2012). A decade post WHI, menopausal hormone therapy comes full circle—Need for independent commission. Climacteric, 15(4), 320–325.
Van Caenegem, E., Wierckx, K., Taes, Y., Dedecker, D., Van de Peer, F., Toye, K., et al. (2012). Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. The Journal of Clinical Endocrinology and Metabolism, 97(7), 2503–2511.
van Haarst, E. P., Newling, D. W., Gooren, L. J., Asscheman, H., & Prenger, D. M. (1998). Metastatic prostatic carcinoma in a male-to-female transsexual. British Journal of Urology, 81(5), 776.
van Kesteren, P. J., Asscheman, H., Megens, J. A., & Gooren, L. J. (1997). Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology, 47(3), 337–342.
van Kesteren, P., Lips, P., Deville, W., Popp-Snijders, C., Asscheman, H., Megens, J., et al. (1996). The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. The Journal of Clinical Endocrinology and Metabolism, 81(6), 2227–2232.
van Kesteren, P., Lips, P., Gooren, L. J., Asscheman, H., & Megens, J. (1998). Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clinical Endocrinology, 48(3), 347–354.
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., et al. (2012). Osteoporosis in men: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 97(6), 1802–1822.
Wierckx, K., Mueller, S., Weyers, S., Van Caenegem, E., Roef, G., Heylens, G., et al. (2012). Long-term evaluation of cross-sex hormone treatment in transsexual persons. The Journal of Sexual Medicine, 9(10), 2641–2651. doi:10.1111/j.1743-6109.2012.02876.x.
Wierckx, K., Stuyver, I., Weyers, S., Hamada, A., Agarwal, A., De Sutter, P., et al. (2012). Sperm freezing in transsexual women. Archives of Sexual Behavior, 41(5), 1069–1071.
Wierckx, K., Van Caenegem, E., Pennings, G., Elaut, E., Dedecker, D., Van de Peer, F., et al. (2012). Reproductive wish in transsexual men. Human Reproduction, 27(2), 483–487.
Wigertz, A., Lonn, S., Mathiesen, T., Ahlbom, A., Hall, P., & Feychting, M. (2006). Risk of brain tumors associated with exposure to exogenous female sex hormones. American Journal of Epidemiology, 164(7), 629–636.
Yeap, B. B. (2009). Are declining testosterone levels a major risk factor for ill-health in aging men? International Journal of Impotence Research, 21(1), 24–36.
Yeap, B. B., Chubb, S. A., Hyde, Z., Jamrozik, K., Hankey, G. J., Flicker, L., et al. (2009). Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: The health in men study. European Journal of Endocrinology, 161(4), 591–598.
Zitzmann, M., Erren, M., Kamischke, A., Simoni, M., & Nieschlag, E. (2005). Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. The Journal of Clinical Endocrinology and Metabolism, 90(12), 6603–6608.
Acknowledgements
Financial support was received from Stichting Reproductieve Geneeskunde, Amsterdam, the Netherlands.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gooren, L., Asscheman, H. (2014). Sex Reassignment: Endocrinological Interventions in Adults with Gender Dysphoria. In: Kreukels, B., Steensma, T., de Vries, A. (eds) Gender Dysphoria and Disorders of Sex Development. Focus on Sexuality Research. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-7441-8_14
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7441-8_14
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-7440-1
Online ISBN: 978-1-4614-7441-8
eBook Packages: Behavioral ScienceBehavioral Science and Psychology (R0)